Cancer Trials Ireland > Cancer Trials > Lymphoma & blood cancers

DSSG Group: Lymphoma & blood cancers

CPD-DARA

Name No. For Patients with Purpose
CPD-DARA 19-17

The target population for this study are patients with relapsed/refractory multiple myeloma (MM). Patients will have a confirmed diagnosis of MM, with measurable disease as per IMWG criteria, in the second relapse and beyond (third line of therapy and beyond)

This study is a Phase Ib, open label, single arm, adaptive multi-centre clinical study of Cyclophosphamide, Pomalidomide, Dexamethasone and Daratumumab (CPD-DARA) in patients with relapsed/refractory multiple myeloma

MOR208C310

Name No. For Patients with Purpose
MOR208C310 20-35

Newly-diagnosed diffuse large B-cell lymphoma (DLBCL).

This Study is comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL).

INDEPENDENCE ACE-536-MF-002

Name No. For Patients with Purpose
INDEPENDENCE ACE-536-MF-002 20-34

Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

This Study is to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions.

HOVON 156

Name No. For Patients with Purpose
HOVON 156 19-16

Newly diagnosed diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2 with FLT3 mutations eligible for intensive chemotherapy

This trial will compare Gilteritinib and midostaurin in combination with induction and consolidation therapy followed by one year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy

HOVON 150

Name No. For Patients with Purpose
HOVON 150 19-18

Newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2 with an IDH1 or IDH2 mutation, eligible for intensive chemotherapy

This trial will compare ivosidenib and enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, eligible for intensive chemotherapy

BCNI GMI-1271-301

Name No. For Patients with Purpose
BCNI GMI-1271-301 21-08

Relapsed/Refractory Acute Myeloid Leukemia (AML)

This Study is to Determine the Effficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukaemia

CLL17

Name No. For Patients with Purpose
CLL17 20-22

Previously untreated Chronic Lymphocytic Leukaemia (CLL)

This trial will compare the efficacy of continuous ibrutinib monotherapy with fixed-duration venetoclax plus obinutuzumab and fixed-duration ibrutinib plus venetoclax in patients with previously untreated CLL

MO40598

Name No. For Patients with Purpose
MO40598 CTRIAL-IE 18-47

Lymphoma.

This study will evaluate the safety and efficacy of Polatuzumab Vedotin (Pola) in combination with Mabthera plus Gemcitabine plus Oxaliplatin (R-GemOx) versus R-GemOx

FEDR-MF-002/FREEDOM-2

Name No. For Patients with Purpose
FEDR-MF-002/FREEDOM-2 CTRIAL-IE 19-40

Primary Myelofibrosis, Post-PV or Post-ET Myelofibrosis

This study will assess the efficacy and safety of fedratinib compared to best available therapy.

Paradigme (LYMRIT-37-01)

Name No. For Patients with Purpose
Paradigme (LYMRIT-37-01) 18-15

Follicular Lymphoma that did not respond to treatment or recurred after chemotherapy or immunotherapy treatment.

To investigate the efficacy and safety of a new drug called Betalutin®. One dose of Betalutin® is given to patients. Betalutin® is an antibody which targets a protein on lymphoma cancer cells together with radioactivity to kill the cancer cells. Two doses of Betalutin® are used in this clinical trial and all patients receive Betalutin®. Patients will be requested to return to clinic for up to 5 years to have their cancer assessed and to collect any side effects.